Related Experiment Videos

Familial infantile apnea and immature beta oxidation

A K Iafolla1, I B Browning, C R Roe

  • 1Division of Biochemical Genetics, Duke University Medical Center, Durham, North Carolina 27710 USA.

Pediatric Pulmonology
|September 1, 1995
PubMed

Insights

Inborn errors of fatty acid metabolism can cause infant breathing issues and sudden infant death syndrome (SIDS). Early L-carnitine treatment improved siblings with these metabolic defects, preventing SIDS.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Genetics

Background:

  • Inborn errors of fatty acid metabolism (FAWM) are associated with significant infant morbidity and mortality, including apnea, periodic breathing, and sudden infant death syndrome (SIDS).
  • Metabolic pathways crucial for development mature during gestation and postnatally, making infants vulnerable to disruptions.
  • Early recognition and therapeutic intervention are critical for preventing adverse outcomes in affected infants.

Observation:

  • A family presented with three siblings exhibiting apnea and periodic breathing.
  • One infant experienced a witnessed sudden infant death (SIDS).
  • The surviving two siblings demonstrated biochemical defects suggestive of a non-specific beta-oxidation abnormality.

Findings:

  • The two surviving siblings were treated with L-carnitine supplementation.
  • L-carnitine therapy led to rapid resolution of both respiratory and metabolic abnormalities.
  • Enzyme activity assays for short, medium, and long-chain acyl-CoA dehydrogenases were normal in the treated survivors, indicating a unique or unidentified enzymatic deficiency.

Implications:

  • This case series highlights the importance of routine biochemical evaluation for infants presenting with acute life-threatening events (ALTE), previously known as "near miss" SIDS.
  • Prompt metabolic assessment should also be considered for infants who have died of SIDS to identify underlying treatable disorders.
  • L-carnitine supplementation may be a beneficial therapeutic strategy for infants with specific, yet unidentified, fatty acid oxidation defects presenting with respiratory compromise.

Related Concept Videos